Advertisement
U.S. markets open in 2 hours 15 minutes

Myriad Genetics, Inc. (MYGN)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
21.40-0.09 (-0.42%)
At close: 04:00PM EDT
21.40 -0.00 (-0.00%)
After hours: 04:04PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected
Double Moving Average Crossover

Double Moving Average Crossover

Previous Close21.49
Open21.80
Bid21.37 x 100
Ask21.42 x 100
Day's Range21.33 - 21.80
52 Week Range13.82 - 24.21
Volume467,210
Avg. Volume645,888
Market Cap1.923B
Beta (5Y Monthly)1.96
PE Ratio (TTM)N/A
EPS (TTM)-3.18
Earnings DateMay 01, 2024 - May 06, 2024
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est24.36
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued

Subscribe to Yahoo Finance Plus to view Fair Value for MYGN

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Myriad Genetics, Inc.
    MYGN: Rating increased to a HOLDMYRIAD GENETICS INC has an Investment Rating of HOLD; a target price of $19.000000; an Industry Subrating of Low; a Management Subrating of Medium; a Safety Subrating of Low; a Financial Strength Subrating of Medium; a Growth Subrating of Medium; and a Value Subrating of Medium.
    Rating
    Fair Value
    Economic Moat
    yesterdayArgus Research
View more
  • Zacks

    Myriad Genetics (MYGN) Wins Foundational Patent for MRD Assay

    Myriad Genetics' (MYGN) new patent grant is likely to bolster the ability to deliver a tumor-informed, high-definition MRD assay to the market.

  • GlobeNewswire

    Myriad Genetics Announces Foundational Patent Granted for Molecular Residual Disease (MRD) with Early Priority Date

    SALT LAKE CITY, March 21, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced that the United States Patent and Trademark Office has issued a patent that will strengthen its ability to deliver a tumor-informed, high-definition, molecular residual disease (MRD) assay to market. U.S. patent 11,932,910, entitled Combinatorial DNA Screening, covers Myriad’s foundational and proprietary method of preparing cell free DNA.

  • GlobeNewswire

    Myriad Genetics Announces Patent Granted for SneakPeek® Snap Device

    SALT LAKE CITY, March 20, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced that the U.S. Patent and Trademark Office has granted a patent that covers the use of push-button blood collection devices for PCR-based fetal sex determination. U.S. Patent No. 11,932,907, titled Fetal Sex Determination Using Capillary Blood From Upper Arm, provides protection for Myriad’s SneakPeek Snap® products in the U.S through 2040.